Skip to content

Study · Animal study (in vivo) · rat · 2003

3 results

Role of MC4 receptors in the depressor and bradycardic effects of alpha-MSH in the nucleus tractus solitarii of the rat.

Pavia JM, Schiöth HB, Morris MJ

Neuroreport1 Apr 2003Cited by 22 (Europe PMC)

PMID12692467 (opens in a new tab)DOI10.1097/00001756-200304150-00009 (opens in a new tab)PepBankPUB-12692467
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetised male rats, melanotan II injected into the nucleus tractus solitarii rapidly decreased blood pressure.

    In plain wordsIn anaesthetised rats, melanotan II injected into a brainstem area quickly lowered blood pressure.

    Peptide
    Melanotan II
    Outcome
    DecreaseBlood pressure
    Study

    ratn: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20-500 pmol · injection into the nucleus tractus solitariiAs given in this study (rat).

    Source sentences

    Summary
    Both alpha-MSH (250 pmol) and MTII (20-500 pmol) produced a rapid decrease in blood pressure and heart rate after injection into the nucleus tractus solitarii (NTS) of urethane-anaesthetised male Sprague-Dawley rats.
    1 context sentence
    Summary · context
    This study investigated the cardiovascular effects of central injection of alpha-MSH and a potent cyclic MC3/4 receptor agonist, MTII, in the presence and absence of the newly developed MC4 receptor selective antagonist, HS014.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetised male rats, melanotan II injected into the nucleus tractus solitarii rapidly decreased heart rate.

    In plain wordsIn anaesthetised rats, melanotan II injected into a brainstem area quickly slowed the heart rate.

    Peptide
    Melanotan II
    Outcome
    DecreaseHeart rate
    Study

    ratn: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    20-500 pmol · injection into the nucleus tractus solitariiAs given in this study (rat).

    Source sentences

    Summary
    Both alpha-MSH (250 pmol) and MTII (20-500 pmol) produced a rapid decrease in blood pressure and heart rate after injection into the nucleus tractus solitarii (NTS) of urethane-anaesthetised male Sprague-Dawley rats.
    1 context sentence
    Summary · context
    This study investigated the cardiovascular effects of central injection of alpha-MSH and a potent cyclic MC3/4 receptor agonist, MTII, in the presence and absence of the newly developed MC4 receptor selective antagonist, HS014.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, prior blockade of the nucleus tractus solitarii with the MC4 receptor antagonist HS014 attenuated, dose-dependently, the cardiovascular responses to melanotan II.

    In plain wordsIn rats, a drug that blocks the MC4 receptor reduced the blood pressure and heart rate effects of melanotan II.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlockade of cardiovascular responses by the MC4 antagonist HS014
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    20-500 pmol · injection into the nucleus tractus solitariiAs given in this study (rat).

    Source sentences

    Summary
    These responses were attenuated in a dose-dependent manner by prior local NTS blockade with HS014 (20 or 100 pmol), providing evidence for the role of the MC4 receptor in the cardiovascular changes following NTS injection of melanocortins in the rat.
    1 context sentence
    Summary · context
    This study investigated the cardiovascular effects of central injection of alpha-MSH and a potent cyclic MC3/4 receptor agonist, MTII, in the presence and absence of the newly developed MC4 receptor selective antagonist, HS014.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.